SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL. “The amylin receptor is rapidly gaining clinical validation as a key target in obesity, driven by encouraging data from injec ...

Structure Therapeutics (GPCR) FY Conference June 11, 2025 10:40 AM ET Speaker0 Following session is not open to the press. Speaker1 Perfect. Thanks, everyone, who's joining us here at the Goldman Sachs Annual Healthcare Conference. Thrilled to have Ray Stevens from Structured Therapeutics here to join us. Maybe you could just start with a quick overview of the business. I would love to kind of get started there, then we'll dig in. Speaker2 Absolutely, Corinne. So Structured Therapeutics is really built arou ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-41608 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 98-1480821 (Stat ...

Exhibit 99.1 Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025; New preclinical data to be presented at American Diabetes Association (ADA) 85 Scientific Sessions in June 2025 Strong financial position with cash, cash equivalents and shor ...

Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025; New preclinical data to be presented at American Diabetes Association (ADA) 85th Scientific Sessions in June 2025 Strong financial position with cash, cash equivalents and short-term investments of $836.9 million SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWIRE) -- Structure Thera ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-41608 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 98-1480821 (State of ...

Exhibit 99.1 Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling activities underway; First-in- human Phase 1 initiation anticipated by year-end 2025 Strong year-end financial position with cash, cash equivalent and short-term invest ...

Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling activities underway; First-in-human Phase 1 initiation anticipated by year-end 2025 Strong year-end financial position with cash, cash equivalent and short-term investments of $883.5 million SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a ...

Core Insights - The obesity drug sector has faced a downturn, with Structure Therapeutics experiencing an 11% decline in share price due to a competitive advertisement from Hims & Hers Health [1][2][3] Group 1: Market Dynamics - Hims & Hers Health launched a multimillion-dollar advertisement during the Super Bowl, highlighting the urgency of obesity as a health crisis and promoting its compounded semaglutide weight loss treatment [2][3] - The advertisement has raised concerns among investors regarding the competitive landscape for obesity drug developers, particularly affecting established companies like Novo Nordisk and Eli Lilly, as well as clinical-stage firms like Structure Therapeutics [3][5] Group 2: Company Performance - Structure Therapeutics is developing its investigational GS-1290 obesity treatment, which has shown promising results in a phase 2a clinical trial, outperforming Novo Nordisk's leading product, Wegovy [4][5] - Despite the competitive pressures from larger companies and high-profile marketing campaigns, there remains significant potential in the obesity treatment market, although many early-stage developers have yet to successfully commercialize their products [5]

SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March. Guggenheim SMID Cap Biotech Conference Format:Fireside chat and 1x1 meetings Date/time:Wednesday, February 5 at 10:30 a.m. ET Location:New York, NY Webcast link:https: ...